ImmunityBio (IBRX) Cost of Revenue (2025 - 2026)
ImmunityBio (IBRX) reported Cost of Revenue of $238000.0 for Q1 2026, up 310.34% year-over-year from $58000.0 in Q1 2025, and down 37.7% on a QoQ basis from $382000.0 in Q4 2025.
ImmunityBio (IBRX) has 2 years of Cost of Revenue data on file, last reported at $238000.0 in Q1 2026.
- Quarterly Cost of Revenue rose 310.34% year-over-year to $238000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $933000.0 (up 1508.62% YoY) and the FY2025 annual result came in at $753000.0, changed N/A from the prior year.
- Cost of Revenue declined to $238000.0 in Q1 2026 per IBRX's latest filing, from $382000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $382000.0 in Q4 2025 and bottomed at $58000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 238,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |